Board members buys additional shares in Scandinavian ChemoTech AB

Report this content

Scandinavian ChemoTech AB (publ) (“ChemoTech”) announces today that Bengt Engström, board member, has bought 5,000 shares for approximately SEK 162,500 over the stock exchange. His total holding now amounts to 43,000 shares in ChemoTech. Rolf Ehrnström, board member, has bought 10,000 shares for approximately SEK 326,000 over the stock exchange. His total holding now amounts to 20,000 shares in ChemoTech.

“Last week, ChemoTech received CE marking for its system IQwave & TSE (tumour specific electroporation). It was of course an important part of our development, but at the same time only the beginning of the next phase. I am very happy and enthusiastic about seeing members of our board buy additional shares in the company.” - says Mohan Frick, CEO Scandinavian ChemoTech

For more information, please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00E-mail:

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: